Novartis AG (NOVN) Gets a Buy from Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) yesterday and set a price target of ...
Novartis to pay $3.1B for Cambridge biotech led by former Karuna CEO
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...
BioPharma Dive1d
Novartis pays $925M to reel in a startup it helped launch
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
MM&M5d
Novartis’ chief marketing officer on the drugmaker’s Super Bowl ad debut
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
FierceBiotech2d
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
UBS downgrades Novartis AG (NOVN) to a Hold
In a report released today, Matthew Weston from UBS downgraded Novartis AG (NOVN – Research Report) to a Hold, with a price target of ...
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019 ...